NCCN Takes First Steps in Creating Outcomes Database
March 1st 1997FORT LAUDERDALE, Fla--Preliminary data on the treatment of breast and colorectal cancer patients at National Comprehensive Cancer Network (NCCN) member institutions show that the members are in compliance with the network's guidelines, Jane Weeks, MD, MSc, of the Dana-Farber Cancer Institute, said at the second annual NCCN conference.
Panel Urges Continued AZT Use in Pregnancy, Policy Review
March 1st 1997Survey Show Americans Favor Higher Tax WASHINGTON, DC--Americans strongly favor raising the federal excise tax on tobacco, and the majority want Congress to do something to provide health care coverage for the uninsured, according to two polls conducted for the American Cancer Society (ACS).
DNA Data Could Spawn 'Genetic Underclass,' Says Va Physician
March 1st 1997Public policy initiatives and increased physician awareness are needed to maintain a healthy balance between the promise of genetic engineering and the potential for genetic discrimination, a Stanford/Veterans Affairs (VA) physician maintains. His
Apoptosis and Response to Radiation: Implications for Radiation Therapy
March 1st 1997Tumor growth is the result of two opposing processes--cell division and cell loss. As long as division outpaces loss, tumors will continue to grow. The form of "active" cell death called apoptosis is now known to be controlled by specific genes, and it is hoped that manipulating the expression of these genes could shift the balance in favor of cell loss.
Use of Predictors of Recurrence to Plan Therapy for DCIS of the Breast
March 1st 1997The incidence of ductal carcinoma in situ (DCIS) has increased dramatically since the advent of screening mammography in the 1980s. The age-adjusted DCIS incidence rates increased 17.5% annually from 1983 to 1992.[1] The percentage of patients with DCIS treated with mastectomy has decreased from 71% in 1983 to 44% in 1992. The percentage of patients with DCIS undergoing lumpectomy and radiation in 1992 was 23.3% and lumpectomy only was 30.2%.
Infusional Chemoradiation for Operable Rectal Cancer: Post-, Pre-, or Nonoperative Management?
March 1st 1997In this article, Dr. Rich traces the evolution of chemoradiation in cancer of the rectum from its role as adjuvant therapy to its role in neoadjuvant therapy and its potential as definitive therapy. The efficacy of irradiation and fluorouracil (5-FU)-based
Infusional Chemoradiation for Operable Rectal Cancer: Post-, Pre-, or Nonoperative Management?
March 1st 1997In 1994, the results of a randomized intergroup trial coordinated by the North Central Cancer Treatment Group (NCCTG 86-47-51) indicated that protracted fluorouracil (5-FU) infusion during postoperative adjuvant radiation therapy results in
Apoptosis and Response to Radiation: Implications for Radiation Therapy
March 1st 1997Quantitative radiation biology was revolutionized in 1956 when Puck and Marcus published the first cell survival curve, relating radiation dose to the fraction of cells surviving.[1] The term "survival" generated a great deal of discussion at that time and led to the definition of such terms as "reproductive death," "reproductive integrity," and "clonogenicity" (among others), all designed to explain that the end point of cell culture experiments is the loss of the cell's ability to divide indefinitely and produce a sizable visible clone.
Current Status of Patient-Controlled Analgesia in Cancer Patients
March 1st 1997In patients with an advanced disease or a terminal illness, it may become necessary to institute parenteral opioid therapy either on a temporary basis (for acute breakthrough pain) or permanently. Continuous intravenous or subcutaneous opioid infusions have been the mainstay of parenteral opioid therapy for oncologic pain. Patient-controlled analgesia (PCA) now offers an alternative modality, and Drs. Bruera and Ripamonti review the current status of this relatively new technique. Is there any evidence to suggest the superiority of one modality over the other for the treatment of oncologic pain?
Use of Predictors of Recurrence to Plan Therapy for DCIS of the Breast
March 1st 1997The Van Nuys Prognostic Index (VNPI) is, in many ways, the best current approach for classifying patients with ductal carcinoma in situ (DCIS) according to their risk of local recurrence after breast-conserving therapy. However, this index has very important limitations.
Apoptosis and Response to Radiation: Implications for Radiation Therapy
March 1st 1997Apoptosis is a mode of cell death that is currently of intense research interest in developmental and cancer biology. For more than 40 years, radiobiologists have been aware of cells in irradiated specimens that display the
Current Status of Patient-Controlled Analgesia in Cancer Patients
March 1st 1997Patient-controlled analgesia (PCA) is a relatively new technique in which patients are able to self-administer small doses of opioid analgesics when needed. Many different devices are available for opioid infusion, including
Panel Urges Continued AZT Use in Pregnancy, Policy Review
March 1st 1997BETHESDA, Md--A federal advisory committee has recommended continuing the use of AZT (zidovudine) in HIV-infected pregnant women to prevent them from passing the virus on to their newborns. The group also urged the US Public Health Service to thoroughly reassess its guidelines for the use of AZT in pregnant women.
Brachytherapy to Tumor Bed After Lumpectomy a Possible Alternative to External Beam Therapy
February 1st 1997ROYAL OAK, Mich-Interstitial implants that deliver radiation therapy to the tumor bed alone after lumpectomy have been well tolerated with no significant acute or late toxicity in the first 50 patients in a Michigan study. In addition, with three years' median follow-up, no patients have recurred locally or distantly.
Key Gene Plays Crucial Role in Malignant Transformation
February 1st 1997A major gene essential for controlling the synthesis of hereditary material and cell proliferation is also critically involved in determining the extent of malignant growth of cancer cells, reports a study published in a recent issue of the Proceedings of
New Technology Helps Scientists Study Early Cancer
February 1st 1997For years, doctors have looked at tissue biopsies and spotted unusual cells that seem to have early signs of cancer. The problem is that, until recently, doctors have never had the right tools to extract the cells from the tissue, leaving them with no
Survey Finds 122 New Anti-HIV Medicines Currently Being Tested
February 1st 1997WASHINGTON--A new survey of pharmaceutical and biotechnology companies by the Pharmaceutical Research and Manufacturers of America (PhRMA) has identified 122 drugs and vaccines in testing to prevent HIV infection or to treat AIDS and AIDS-related diseases. These drugs are in addition to the 42 medications already approved and on the market in the United States.
President Clinton Unveils National AIDS Policy
February 1st 1997WASHINGTON--President Clin-ton calls his new national AIDS strategy an important milestone in the history of efforts to end the pandemic that has killed more than 343,000 Americans since 1981. "In the 15 years of this epidemic, we have never had such a unified strategy," the President said. "These goals will guide our work in the coming term and, more specifically, in the coming year."
Mammotomy May Reduce Biopsy Sampling Errors
February 1st 1997CHICAGO--A percutaneous breast biopsy method that uses a thin rotating blade to snip off tissue and a vacuum element to withdraw pathological samples is proving to be three times more accurate and two times faster than core needle biopsy, said Roger J. Jackman, MD, of the Department of Diagnostic Radiology, Palo Alto Medical Clinic, Calif, at the annual meeting of the Radiological Society of North America (RSNA).
Ultrasound Advances May Expand Role in Treatment Planning
February 1st 1997CHICAGO--Although ultrasound has been the primary imaging technique used in the assessment of the prostate gland for potential malignancy, it has been secondary to PSA assays and the digital rectal examination as a screening technique because "the cost-benefit ratio is too low to warrant its use," Matthew D. Rifkin, MD, said at the annual meeting of the Radiological Society of North America. New technological refinements of sonographic equipment, however, may allow a bigger role for ultrasound in prostate cancer in the future, said Dr. Rifkin, chair of the Department of Radiology, Albany Medical College, NY.
NIH Consensus Development Statement Sparks Rancor
February 1st 1997BETHESDA, Md--The NIH Consensus Development Conference was unanimous in its decision not to recommend routine screening mammography for women aged 40 to 49, saying that the evidence to date does not show that any possible benefits outweigh potential risks.
Raising the US Retirement Age Could Save Billions in Social Security Payments
February 1st 1997Raising the normal retirement age in the United States to age 70 could save the federal government billions of dollars each year and help shore up the ailing Social Security trust fund over the long term, according to two university researchers.